(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 March 2006 (09.03.2006)

PCT

(10) International Publication Number
WO 2006/026135 A3

(51) International Patent Classification:

C07D 401/04 (2006.01)	***A61K 31/53*** (2006.01)
C07D 401/14 (2006.01)	***A61K 31/506*** (2006.01)
C07D 403/04 (2006.01)	***A61K 31/4427*** (2006.01)
C07D 403/14 (2006.01)	***A61P 11/00*** (2006.01)
C07D 413/04 (2006.01)	***A61P 11/06*** (2006.01)
C07D 413/14 (2006.01)	***A61P 13/10*** (2006.01)

(21) International Application Number:
PCT/US2005/028969

(22) International Filing Date: 13 August 2005 (13.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/601,721	13 August 2004 (13.08.2004)	US
60/641,796	5 January 2005 (05.01.2005)	US

(71) Applicant *(for all designated States except US)*: **NEUROGEN CORPORATION** [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BLUM, Charles, A.** [US/US]; 785 W. Pond Meadow Road, Westbrook, CT 06498 (US). **BRIELMANN, Harry** [US/US]; 14 Elm Street, Guilford, CT 06437 (US). **CHENARD, Bertrand, L.** [US/US]; 7 Whaling Drive, Waterford, CT 06385 (US). **ZHENG, Xiaozhang** [CN/US]; 10 Roby Court, Branford, CT 06405 (US).

(74) Agents: **ALEXANDER, Ph.D., John, B.** et al.; Edwards & Angell, LLP, P.O. Box 55874, Boston, MA 02205 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
15 June 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES



(I)

(57) Abstract: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity *in vivo* or *in vitro*,and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

WO 2006/026135 A3